EODData

MEMBERSHIP REGISTER LOG IN

FRA, 0L8: Lantheus Holdings Inc

29 Sep 2025
LAST:

43.02

CHANGE:
 0.53		OPEN:
42.81		HIGH:
43.45		ASK:
0.00		VOLUME:
415
CHG(%):
1.22		PREV:
43.55		LOW:
42.81		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
29 Sep 2542.8143.4542.8143.02415
26 Sep 2543.5343.5543.5343.55100
25 Sep 2544.8344.8344.8344.8310
24 Sep 2543.6843.6843.6843.6810
23 Sep 2542.0642.0642.0642.0610
22 Sep 2542.9042.9042.9042.9010
19 Sep 2543.2643.2643.2643.2670
18 Sep 2542.9042.9042.9042.9070
17 Sep 2543.4344.0843.4344.0870
16 Sep 2543.4943.4943.4943.4910

COMPANY PROFILE

Name:Lantheus Holdings Inc
About:Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Sector:Healthcare
Address:201 Burlington Road, Bedford, MA, United States, 01730
Website:https://www.lantheus.com
ISIN:US5165441032
LEI:5299005HUB5IOJGO7S39

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:14.26
Price to Book:3.12
Price to Sales:2.11
EBITDA:494M
Shares:67.99M
Market Cap:2.925B

TECHNICAL INDICATORS

MA5:43.43
MA10:43.38
MA20:44.54
MA50:49.27
MA100:58.67
MA200:73.18
STO9:34.66
STO14:21.10
RSI14:42.45
WPR14:-78.38
MTM14:-1.59
ROC14:-0.04
ATR:1.11
Week High:44.83
Week Low:42.06
Month High:47.05
Month Low:42.06
Year High:107.38
Year Low:41.72
Volatility:37.84